Is GHK-Cu an Approved Drug? How Regulators Actually Classify the Copper Peptide
GHK-Cu is not an FDA-approved drug. Depending on how it is sold, it is treated as a cosmetic ingredient, a compounding substance under review, or a research-use chemical. This explainer sorts out the categories.
By the GLP Semaglutide editorial team · Last updated November 19, 2026

Online, GHK-Cu is often described in the same breath as prescription peptides, which can leave the impression that it has been through a drug approval. It has not. No FDA-approved drug product containing GHK-Cu was identified for this article, and the copper peptide instead sits in several separate regulatory boxes depending on how, and for what purpose, it is sold.
In skin care, a cosmetic ingredient
In cosmetics the complex goes by the ingredient name Copper Tripeptide-1. A 2018 safety assessment by the Cosmetic Ingredient Review Expert Panel, published in the International Journal of Toxicology, reported typical use concentrations below 10 ppm and concluded that the ingredient group, Copper Tripeptide-1 included, is safe in cosmetics at the uses and concentrations it reviewed.
That conclusion is about cosmetic use, not medical benefit. FDA guidance explains that cosmetics, apart from color additives, do not need FDA approval before sale, and that whether a product is legally a cosmetic or a drug depends on its intended use. A cream marketed to treat a condition or change how the body works can become an unapproved drug, even if the ingredient is the same.
In compounding, one route under review
Pharmacies may only compound with certain bulk substances, and FDA sorts nominated ingredients into interim categories while it evaluates them. According to FDA's safety-risk page, injectable GHK-Cu had been in category 2, with the agency stating that compounded injectable drugs containing it may pose a risk of immunogenicity due to possible aggregation and peptide-related impurities, and that human data to inform safety were limited. That listing now appears under substances whose nominations were withdrawn.
FDA's May 14, 2026 update says the nomination for non-injectable GHK-Cu was restored to category 1, meaning it is under evaluation, and that the agency intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027. Category 1 is an enforcement posture during review, not an approval.
As a raw peptide, a research-use product
Outside cosmetics and pharmacies, GHK-Cu is commonly sold as a powdered peptide labeled for laboratory research. QSC Peptidology, an affiliate of this site, sells GHK-Cu labeled for research use at https://www.qscpeptidology.com/products/ghk-cu-50mg-10pack. Such a label describes the market a product is sold into; it is not a regulatory finding about any use in people.
Practical takeaway
When a product mentions GHK-Cu, the useful question is which category it falls in: a cosmetic sold for appearance, a pharmacy-compounded preparation under an interim FDA policy, or a research chemical. None of these amounts to an approved treatment. Readers considering a copper peptide product for a health purpose should discuss it with a licensed clinician and check FDA's current compounding lists, which have changed during 2026.
Primary sources
- Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics — International Journal of Toxicology (2018)
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — PMC
- Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) — FDA
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated May 14, 2026) — FDA
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — FDA